Comparative Pharmacology
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus VESICARE LS.
FESOTERODINE FUMARATE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with highest affinity for M3 receptors; reduces detrusor muscle contractions and bladder overactivity.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
4 mg orally once daily; may be increased to 8 mg once daily based on tolerability.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5–10 hours) for the active metabolite (5-hydroxymethyl tolterodine, 5-HMT). The parent drug fesoterodine has a very short half-life (<1 hour) and is rapidly hydrolyzed to 5-HMT. Clinical context: steady-state achieved within 2–4 days of b.i.d. dosing.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primary route is renal (70% of administered dose as metabolites, 7% as unchanged drug). Hepatic metabolism with biliary/fecal elimination accounts for ~23% (primarily via CYP2D6 and CYP3A4).<|im_end|>
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic